Targeting Bruton's tyrosine kinase in B cell malignancies

RW Hendriks, S Yuvaraj, LP Kil - Nature Reviews Cancer, 2014 - nature.com
Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and
functions as an important regulator of cell proliferation and cell survival in various B cell …

Bruton's tyrosine kinase: an emerging key player in innate immunity

ANR Weber, Z Bittner, X Liu, TM Dang… - Frontiers in …, 2017 - frontiersin.org
Bruton's tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell
receptor signaling in the development and functioning of adaptive immunity. Growing …

Bruton's tyrosine kinase inhibitors (Btkis): review of Preclinical studies and evaluation of clinical trials

D Rozkiewicz, JM Hermanowicz, I Kwiatkowska… - Molecules, 2023 - mdpi.com
In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK)
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

J Cicenas, L Tamosaitis, K Kvederaviciute, R Tarvydas… - Medical oncology, 2017 - Springer
Cancers are the group of diseases, which arise because of the uncontrolled behavior of
some of the genes in our cells. There are possibilities of gene amplifications …

Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach

D Sridaran, E Bradshaw, C DeSelm, R Pachynski… - Cell Reports …, 2023 - cell.com
Cancer immunotherapy has gained traction in recent years owing to remarkable tumor
clearance in some patients. Despite the notable success of immune checkpoint blockade …

Ibrutinib in the treatment of solid tumors: Current state of knowledge and future directions

K Szklener, A Michalski, K Żak, M Piwoński… - Cells, 2022 - mdpi.com
Bruton's Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both
physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became …

Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs

M Gámez-Chiachio, D Sarrió, G Moreno-Bueno - Cancers, 2022 - mdpi.com
Simple Summary Drug resistance is the “Achilles' heel” in current oncology. In this sense,
the clinical management of HER2 breast carcinomas (tumors with overexpression …

Targeting the NLRP3 Inflammasome via BTK

ANR Weber - Frontiers in Cell and Developmental Biology, 2021 - frontiersin.org
The NLRP3 inflammasome represents a critical inflammatory machinery driving pathology in
many acute (eg, myocardial infarction or stroke) and chronic (Alzheimer's disease …

Fluorescence anisotropy imaging in drug discovery

C Vinegoni, PF Feruglio, I Gryczynski… - Advanced drug delivery …, 2019 - Elsevier
Non-invasive measurement of drug-target engagement can provide critical insights in the
molecular pharmacology of small molecule drugs. Fluorescence polarization/fluorescence …

Bruton's tyrosine kinase and its isoforms in cancer

X Wang, L Kokabee, M Kokabee… - Frontiers in cell and …, 2021 - frontiersin.org
Bruton's tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the
development, maturation, and signaling of B cells. BTK has been found to regulate cell …